PROSEEK: A Phase 2 Study in Early Parkinson's Disease Patients Evaluating the Safety and Effectiveness of Abl Tyrosine Kinase
This study will determine if an investigational drug reduces the rate of progression of early-stage Parkinson’s disease (PD) versus placebo over 40 weeks.
Who may be eligible to participate?
Men or women 50 years of age and above, with a diagnosis of PD with symptoms beginning in the past three years and who are not on any dopaminergic treatment.
Other inclusion and exclusion criteria may apply.
What does participation involve?
This study will have 11 study visits over a period of about 44 weeks, not including the Screening Visit.
Screening assessments will be performed over a period of up to six weeks during the “Screening Period”.
Subjects who qualify for this study will be randomly assigned to receive either 96mg of investigational study drug, 192mg of investigational study drug, or placebo (no drug) capsules.
Pinky Agarwal, MD, FAAN, Booth Gardner Parkinson’s Care Center